Literature DB >> 1063049

Cyclophosphamide-asparaginase- vincristine-prednisone induction therapy in childhood acute lymphocytic and nonlymphocytic leukemia.

D M Komp, S L George, J Falletta, V J Land, K A Starling, G B Humphrey, J Lowman.   

Abstract

A remission-induction regimen for childhood leukemia using cyclophosphamide, asparaginase, vincristine, and prednisone (CAVP) was compared to standard vincristine-prednisone (VP) induction. The more intensive regimen was associated with a lower complete remission rate (81% vs 93%) and a higher early death rate from infection (15% vs 5%) for acute lymphocytic leukemia. In contrast, complete remission was achieved in 58% of children with acute nonlymphocytic leukemia treated with CAVP compared to 18% for VP. Early death rates were similar (27% vs 25%). These observations corroborate previous studies in childhood nonlymphocytic leukemia showing activity for asparaginase. Preliminary analysis of remission duration and survival for responders shows no advantage for those who survived the more intensive induction.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1063049     DOI: 10.1002/1097-0142(197603)37:3<1243::aid-cncr2820370303>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Current management of childhood acute lymphocytic leukemia.

Authors:  H Ekert
Journal:  Indian J Pediatr       Date:  1981 Jul-Aug       Impact factor: 1.967

Review 2.  Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis.

Authors: 
Journal:  Br J Haematol       Date:  2009-02-22       Impact factor: 6.998

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.